Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
8 pending office actions • 8 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
The University of Birmingham has 7 pending office actions in Biotechnology & Pharmaceuticals. The portfolio spans 7 distinct examiners and 7 distinct art units, meaning every pending matter has its own examiner and art-unit assignment in the available data.
BERKE-SCHLESSEL, DAVID W is the busiest examiner, with 1 pending matter. No examiner or art unit carries more than one listed matter, so centralized examiner-specific planning is not indicated.
The breadth of assignments makes docket-level coordination important, while substantive response strategy will need to account for each application’s separate examination context. The profile does not show whether the matters are technically related.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (12%) |
| §112 only | 1 (12%) |
| Multi-statute (no §101) | 6 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERKE-SCHLESSEL, DAVID W | 1 | 66.8% | +31.5% |
| HOWARD, ZACHARY C | 1 | 63.9% | +37.7% |
| REDDIG, PETER J | 1 | 58.0% | +40.2% |
| LEE, HOI YAN NMN | 1 | 37.5% | +76.2% |
| PAGANO, ALEXANDER R | 1 | 78.7% | +11.4% |
| FAN, LYNN Y | 1 | 47.3% | +49.8% |
| BROWE, DAVID | 1 | 26.7% | +28.0% |
| ROSEBACH, CHRISTINA H.W. | 1 | 59.2% | -34.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17277019 | Functionalized Surface | ROSEBACH, CHRISTINA H.W. | 153d overdue |
| 18033160 | SPRAYABLE ANTIVIRAL FORMULATION | LEE, HOI YAN NMN | 8d |
| 18838225 | GENERATING BONE MARROW ORGANOIDS | BERKE-SCHLESSEL, DAVID W | — |
| 18517633 | T CELL ACTIVATION | HOWARD, ZACHARY C | — |
| 18269308 | NANOBODY TO GLYCOPROTEIN VI | REDDIG, PETER J | — |
| 17311534 | THERAPEUTIC HYDROGEL COMPOSITIONS | BROWE, DAVID | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18009485 | FLUID GEL COMPOSITIONS | FAN, LYNN Y | 11d overdue |
| 18033160 | SPRAYABLE ANTIVIRAL FORMULATION | LEE, HOI YAN NMN | 8d |
| 18028238 | SUPRAMOLECULAR MOLECULES FOR THE TREATMENT OF CANCER | PAGANO, ALEXANDER R | 22d |
| 18838225 | GENERATING BONE MARROW ORGANOIDS | BERKE-SCHLESSEL, DAVID W | — |
| 18517633 | T CELL ACTIVATION | HOWARD, ZACHARY C | — |
| 18269308 | NANOBODY TO GLYCOPROTEIN VI | REDDIG, PETER J | — |
| 17311534 | THERAPEUTIC HYDROGEL COMPOSITIONS | BROWE, DAVID | — |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| 1674 | 1 |
| 1646 | 1 |
| 1693 | 1 |
| 1692 | 1 |
| 1759 | 1 |
| 1617 | 1 |
| 1766 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18838225 | GENERATING BONE MARROW ORGANOIDS | BERKE-SCHLESSEL, DAVID W | 1651 | §102§103 | Non-Final OA | — | Pending | Aug 13, 2024 |
| 18517633 | T CELL ACTIVATION | HOWARD, ZACHARY C | 1674 | §102§112 | Non-Final OA | — | Pending | Nov 22, 2023 |
| 18269308 | NANOBODY TO GLYCOPROTEIN VI | REDDIG, PETER J | 1646 | §102§112 | Non-Final OA | — | Pending | Jun 23, 2023 |
| 18033160 | SPRAYABLE ANTIVIRAL FORMULATION | LEE, HOI YAN NMN | 1693 | §102§103§112Other | Final Rejection | 8d | Pending | Apr 21, 2023 |
| 18028238 | SUPRAMOLECULAR MOLECULES FOR THE TREATMENT OF CANCER | PAGANO, ALEXANDER R | 1692 | §112 | Final Rejection | 22d | Pending | Mar 24, 2023 |
| 18009485 | FLUID GEL COMPOSITIONS | FAN, LYNN Y | 1759 | §103 | Final Rejection | 11d overdue | Pending | Dec 09, 2022 |
| 17311534 | THERAPEUTIC HYDROGEL COMPOSITIONS | BROWE, DAVID | 1617 | §103§112 | Non-Final OA | — | Pending | Jun 07, 2021 |
| 17277019 | Functionalized Surface | ROSEBACH, CHRISTINA H.W. | 1766 | §103§112 | Non-Final OA | 153d overdue | Pending | Mar 17, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe University of Birmingham has 8 pending office actions as of October 2026, spread across 8 art units and 8 examiners.
David W Berke-Schlessel has the most, with 1 of The University of Birmingham's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
